Skip to main content
. 2019 Jul 29;20(15):3700. doi: 10.3390/ijms20153700

Figure 1.

Figure 1

Checkpoint kinase 1 (CHK1) inhibition activates downstream targets of p53. (A) Cell viability assay of four MYCN-amplified neuroblastoma (NB) cell lines after exposure to dimethyl sulfoxide (DMSO) (NT) 1 μM CHK1 inhibitor (CHK1i) (PF-477736) for the indicated times. Data are presented as the mean ± SD of three independent experiments. * p < 0.05. (B) Microarray analysis of CHK1i-sensitive SMS-SAN cell line and the relatively insensitive NB-39-nu cell line at 36 h after treatment with 1 μM CHK1i or DMSO. (C) Immunoblot analysis of basal levels of CHK1, MYCN, and p53 in NB cells. β-actin was used as a loading control. Representative numbers were normalized to the intensity of the indicated bands.